FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923312278> ?p ?o ?g. }

• W2923312278 endingPage "S67" @default.
• W2923312278 startingPage "S67" @default.
• W2923312278 abstract "Research has identified cancer survivors as a growing demographic of patients with opioid use disorder. Providers of this group may continue opioid medications despite remission of cancer, as clinical findings may be complicated by difficulty identifying a clear pain generator. We present a 57-year-old man with history of retroperitoneal liposarcoma that presented to the emergency department at a Veterans Affairs Hospital fifteen times between March 2017 and October 2018 with abdominal pain, nausea, and vomiting. He had been in remission since 2016 after treatment with chemotherapy and radiation. Of the multiple hospital visits, he was admitted five times and seen by multiple specialists, including gastroenterology, hematology-oncology, palliative care, and pain management. Because of the severity of pain and recent cancer remission, he underwent multiple comprehensive evaluations, including multiple CT scans, esophagogastroduodenoscopy, and PET scan. No evidence of recurrence was found. The patient was provided intravenous opioid therapy with relief at each encounter. After review of his clinical course, Pain providers identified he was consistently presenting prior to the anticipated renewal date of his opioids. The patient's symptoms were felt to be consistent with opioid withdrawal. Given the severity of symptoms and lack of indication for continuing opioids, the patient was determined to be a candidate for medication assisted therapy. He was subsequently tapered off opioids and started on buprenorphine 4 mg BID. He was titrated to 8 mg TID by addiction psychiatry with significant improvement in abdominal pain, sleep, and appetite. Since starting MAT, the patient hasn't presented to the ED for care. This case report highlights the need for vigilance against the development of OUD in cancer survivors. It also demonstrates the healthcare costs and concerns of continuing opioid therapy without indication. Identifying opioid use disorder and utilizing MAT may be crucial to treating OUD in this population. Research has identified cancer survivors as a growing demographic of patients with opioid use disorder. Providers of this group may continue opioid medications despite remission of cancer, as clinical findings may be complicated by difficulty identifying a clear pain generator. We present a 57-year-old man with history of retroperitoneal liposarcoma that presented to the emergency department at a Veterans Affairs Hospital fifteen times between March 2017 and October 2018 with abdominal pain, nausea, and vomiting. He had been in remission since 2016 after treatment with chemotherapy and radiation. Of the multiple hospital visits, he was admitted five times and seen by multiple specialists, including gastroenterology, hematology-oncology, palliative care, and pain management. Because of the severity of pain and recent cancer remission, he underwent multiple comprehensive evaluations, including multiple CT scans, esophagogastroduodenoscopy, and PET scan. No evidence of recurrence was found. The patient was provided intravenous opioid therapy with relief at each encounter. After review of his clinical course, Pain providers identified he was consistently presenting prior to the anticipated renewal date of his opioids. The patient's symptoms were felt to be consistent with opioid withdrawal. Given the severity of symptoms and lack of indication for continuing opioids, the patient was determined to be a candidate for medication assisted therapy. He was subsequently tapered off opioids and started on buprenorphine 4 mg BID. He was titrated to 8 mg TID by addiction psychiatry with significant improvement in abdominal pain, sleep, and appetite. Since starting MAT, the patient hasn't presented to the ED for care. This case report highlights the need for vigilance against the development of OUD in cancer survivors. It also demonstrates the healthcare costs and concerns of continuing opioid therapy without indication. Identifying opioid use disorder and utilizing MAT may be crucial to treating OUD in this population." @default.
• W2923312278 created "2019-04-01" @default.
• W2923312278 creator A5003595086 @default.
• W2923312278 creator A5025343409 @default.
• W2923312278 creator A5029813737 @default.
• W2923312278 creator A5037386890 @default.
• W2923312278 date "2019-04-01" @default.
• W2923312278 modified "2023-09-23" @default.
• W2923312278 title "(372) Suboxone Therapy for Cancer Survivors with Opioid Use Disorder: A Case Report" @default.
• W2923312278 doi "https://doi.org/10.1016/j.jpain.2019.02.068" @default.
• W2923312278 hasPublicationYear "2019" @default.
• W2923312278 type Work @default.
• W2923312278 sameAs 2923312278 @default.
• W2923312278 citedByCount "0" @default.
• W2923312278 crossrefType "journal-article" @default.
• W2923312278 hasAuthorship W2923312278A5003595086 @default.
• W2923312278 hasAuthorship W2923312278A5025343409 @default.
• W2923312278 hasAuthorship W2923312278A5029813737 @default.
• W2923312278 hasAuthorship W2923312278A5037386890 @default.
• W2923312278 hasBestOaLocation W29233122781 @default.
• W2923312278 hasConcept C121608353 @default.
• W2923312278 hasConcept C126322002 @default.
• W2923312278 hasConcept C159110408 @default.
• W2923312278 hasConcept C170493617 @default.
• W2923312278 hasConcept C2776029756 @default.
• W2923312278 hasConcept C2778451229 @default.
• W2923312278 hasConcept C2778904085 @default.
• W2923312278 hasConcept C2779526319 @default.
• W2923312278 hasConcept C2780580376 @default.
• W2923312278 hasConcept C2780852908 @default.
• W2923312278 hasConcept C2780955771 @default.
• W2923312278 hasConcept C2781063702 @default.
• W2923312278 hasConcept C2781143854 @default.
• W2923312278 hasConcept C2991975920 @default.
• W2923312278 hasConcept C2994186709 @default.
• W2923312278 hasConcept C42219234 @default.
• W2923312278 hasConcept C71924100 @default.
• W2923312278 hasConceptScore W2923312278C121608353 @default.
• W2923312278 hasConceptScore W2923312278C126322002 @default.
• W2923312278 hasConceptScore W2923312278C159110408 @default.
• W2923312278 hasConceptScore W2923312278C170493617 @default.
• W2923312278 hasConceptScore W2923312278C2776029756 @default.
• W2923312278 hasConceptScore W2923312278C2778451229 @default.
• W2923312278 hasConceptScore W2923312278C2778904085 @default.
• W2923312278 hasConceptScore W2923312278C2779526319 @default.
• W2923312278 hasConceptScore W2923312278C2780580376 @default.
• W2923312278 hasConceptScore W2923312278C2780852908 @default.
• W2923312278 hasConceptScore W2923312278C2780955771 @default.
• W2923312278 hasConceptScore W2923312278C2781063702 @default.
• W2923312278 hasConceptScore W2923312278C2781143854 @default.
• W2923312278 hasConceptScore W2923312278C2991975920 @default.
• W2923312278 hasConceptScore W2923312278C2994186709 @default.
• W2923312278 hasConceptScore W2923312278C42219234 @default.
• W2923312278 hasConceptScore W2923312278C71924100 @default.
• W2923312278 hasIssue "4" @default.
• W2923312278 hasLocation W29233122781 @default.
• W2923312278 hasOpenAccess W2923312278 @default.
• W2923312278 hasPrimaryLocation W29233122781 @default.
• W2923312278 hasRelatedWork W1919200285 @default.
• W2923312278 hasRelatedWork W2015925754 @default.
• W2923312278 hasRelatedWork W2230978096 @default.
• W2923312278 hasRelatedWork W2335406452 @default.
• W2923312278 hasRelatedWork W2362169642 @default.
• W2923312278 hasRelatedWork W2395529704 @default.
• W2923312278 hasRelatedWork W2601393134 @default.
• W2923312278 hasRelatedWork W3158082504 @default.
• W2923312278 hasRelatedWork W50145246 @default.
• W2923312278 hasRelatedWork W2108644667 @default.
• W2923312278 hasVolume "20" @default.
• W2923312278 isParatext "false" @default.
• W2923312278 isRetracted "false" @default.
• W2923312278 magId "2923312278" @default.
• W2923312278 workType "article" @default.